Table 104Results of deterministic sensitivity analyses

Scenario testedICERs
Utility scores estimated from an SG instrumentAcamprosate versus standard care: £10,087
Naltrexone extendedly dominated
Increased intensity of patient monitoring over a 12-month periodAcamprosate versus naltrexone: £13,323
Naltrexone versus standard care: £10,789
Monthly cost of relapse is (a) £0; (b) £300
  1. Acamprosate versus standard care: £10,668
    Naltrexone extendedly dominated
  2. Acamprosate is dominant
    Standard care is dominated by both other options


Cover of Alcohol-Use Disorders
Alcohol-Use Disorders: Diagnosis, Assessment and Management of Harmful Drinking and Alcohol Dependence.
NICE Clinical Guidelines, No. 115.
National Collaborating Centre for Mental Health (UK).
Leicester (UK): British Psychological Society; 2011.
Copyright © 2011, The British Psychological Society & The Royal College of Psychiatrists.

All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. Enquiries in this regard should be directed to the British Psychological Society.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.